Correction to “Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression”

Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research. 2021; 51: 880–9. https://doi.org/10.1111/hepr.13644.

In the “Methods” section of the abstract, the text “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with regorafenib followed by sorafenib were enrolled…” was incorrect.

This should have read: “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with sorafenib followed by regorafenib were enrolled…”

We apologize for this error.